Q4 2024 Management View CEO Paula Ragan highlighted 2024 as a transformative year for X4 Pharmaceuticals, with the U.S. approval and launch of XOLREMDI (mavorixafor) for WHIM syndrome, a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback